Need assistance? Whatsapp us at 7574867535 or E-mail us at eventsupport@plexusmd.com Refund Policy

I-OSI Membership Registration

Immuno-Oncology Society of India

The <span \"data-stled-color:#FFFF00;\"><strong>Immuno-Oncology Society of India (I-OSI)</strong> </span>was established with the aim to increase public awareness about <span \"data-stled-color:#FFFF00;\"><strong>immunotherapies, boost basic</strong></span> and <span \"data-stled-color:#FFFF00;\"><strong>clinical research</strong></span> on immuneoncology and provide a forum for interdisciplinary interactions between physicians and scientists. The I-OSI will be a forum to connect basic scientists working in immunology with clinicians to bring lab discoveries to bedside. I-OSI will aim to keep all the stakeholders up-to-date in this rapidly evolving field.
Eligibility
Intake
Certificate
Hands-on Training
ABC Accred.
CME Credits

Agenda

  • <b>President\'s Message</b>
  • <b>I-OSI President Elect</b>
  • <b>Secretary Speaks</b>
Dear I-OSI Members,

During the past decade anti-cancer immunotherapy has evolved from a promising therapeutic option to robust reality that has changed treatment outcomes. The development of cancer vaccines, CAR-T cells, and checkpoint inhibitors are changing the paradigms of clinical cancer management. Immunotherapy is rapidly evolving cancer treatment modality with exciting benefits but also poses unique challenges for patients and the healthcare team. Clinical studies are being initiated at an accelerating pace to test the safety and efficacy of various immunotherapeutic regimens in cancer patients, either as standalone interventions or combined with radiotherapy, antineoplastic agents or epigenetic modulators.

Cancer Immunotherapy is nascent in India. The Immuno-Oncology Society of India (I-OSI) was established with the aim to increase public awareness about immunotherapies, boost basic and clinical research on immuneoncology and provide a forum for interdisciplinary interactions between physicians and scientists. The I-OSI will be a forum to connect basic scientists working in immunology with clinicians to bring lab discoveries to bedside. I-OSI will aim to keep all the stakeholders up-to-date in this rapidly evolving field.

Progress made in human genome sequencing and bioinformatics,detection and understanding of genetic and epigenetic informationof tumors and immune landscapes will help to establish individualized immunotherapy to obtain clinical benefits for more patients.

As the number of immune therapies are expected to rise in the foreseeable future, there are several key issues that remain and require further investigation in order to optimize the anti-cancer potential of this class of agents. Primary and acquired resistance becomes one of the major obstacles, which greatly limits the long lasting effects and wide application of cancer immunotherapy.

In order to optimize benefit and minimize risk there is an urgent need to have predictive biomarkers, identify hyperprogressors, understand themechanisms of resistance and immune related toxicities, decide treatment duration and clinical trial design.

It gives me great pleasure to present the first issue of the I-OSI Newsletter. I take this opportunity to invite all the I-OSI members to actively contribute to the Newsletter by sharing their thoughts and expertise that will create new linkages and foster opportunities for networking.

Warm Regards,

Dr. Shubhada Chiplunkar
President
Immuno-Oncology Society Of India
Dear Friends,

Immunotherapy for malignant diseases has been labeled as the ‘advance of the decade’ and some unbelievable responses in end-stage patients have been recorded. The field has moved from the initial studies on disseminated malignant melanoma to almost all solid tumors and to first line treatment. These advances in solid tumor oncology have been paralleled with the development of CAR T cell therapies for liquid tumors.

he conception of the ImmunoOncology Society of India ( I-OSI) was with the vision, to have a cohesive amalgamation of immunologists and oncologists and the diverse fields whose contributions have resulted in successful development, implementation and assessment of cancer immunotherapy including radiation oncology, pathology, transfusion medicine, surgery and imaging modalities. Real progress can only be made when we have the bench scientists on the same page as the bedside clinicians!

Progress made in human genome sequencing and bioinformatics, detection and understanding of genetic and epigenetic information of tumors and immune landscapes will help to establish individualized immunotherapy to obtain clinical benefits for more patients.

In a country like India, where very few patients are candidates for these very expensive drugs, the need for indigenous research and development of our own immune-therapy molecules and an Indian-Car is the need of the hpur. We strongly feel that the Society will promote development, implementation, and dissemination of scientific, evidence-based and comprehensive management of cancers by immunotherapy, and encourage basic and clinical research in the complex interplay of immunology and oncology.

The birth of the Society and the inauguration of the first newsletter is a proud moment for all of us. I encourage all the members to be dedicated to the academic pursuit and growth of this field and the Society to benefit masses of the patients in the country and the community as a whole.

Warm Regards,

Dr. Hemant Malhotra
President Elect
Immuno-Oncology Society Of India
A journey of a thousand miles begins with a single step.

In India, cancer immunotherapy is at a nascent stage and mostly dependent on import and adoption of technologies and drugs patented in the more developed countries. India, with its huge cancer burden and a largely poor populace is in dire need of new technologies that can rapidly be taken through trials and brought to our patients at affordable costs. This will only be possible if the clinical and scientific community from across diverse fields with an interest in the interplay of immunology and oncology get together and focus their knowledge, skills and energies on this emerging field.

In this context, an interest group formed during the organization of the first Evidence Based Meeting on Immunooncology that was held in Tata Memorial Hospital, Mumbai from the 23rd to 25th of February, 2018. The interest group articulated their thoughts and adopted the “Mumbai Resolution” on 24th February 2018 , that led to the formation of the Immuno-oncology Society of India (IOSI) dedicated to the academic pursuit and growth of this field.

The aims of the society, as incorporated in its Constitution, are as follows:
  • The society shall be a non-profitable organization for promotion and advancement of scientific knowledge and research in immuno-oncology and increasing the awareness amongst both physicians, scientists, patients and other stakeholders regarding immuno-oncology.
  • Increase interdisciplinary interactions among all stakeholders dealing with immune-oncology at national and international level.
  • To encourage basic and clinical research in immuno-oncology and help in translation of laboratory discoveries to patient care.
  • To assist Government and nongovernmental agencies in all matters pertaining to immuno-oncology.
  • To increase public awareness about immuno-oncology and actively promote continuing education to disseminate the state-of-art knowledge on the basic research and treatment of cancer using immunooncology.
  • To strive to develop guidelines on development and management of various aspects of immuno-oncology
  • A list of the executive committee is also displayed in this newsletter and it is obvious that there is adequate representation to all disciplines and all the regions of country to have a true national spirit.

I-OSI will seek to provide a common platform for interaction and mutual collaboration between different specialists and institutes, including industry,sharing a common passion for immuno-oncology. Associations and societies for providing this platform have been constituted in different parts of the world including the Society for Immunooncology (SITC) based in North America.

In India, there are a large number of patients, excellent expertise, and perhaps more importantly, a growing recognition of generating world class basic, clinical and epidemiological data and I-OSI hopefully would provide an appropriate forum to talk, deliberate, and execute quality research.

We are beginning to weave with the faith that nature will give the thread and the IOSI delivers the planned objectives.

Success depends on our perspective and our ingenuity. If we remain open to possibilities and make full use of the resources with each one delivering the best we will achieve our ultimate goal, which goes without saying, is to help our patients and their families.

It takes a whole village to raise a child and I sincerely look forward to your full hear efforts to thoughts and suggestions for the society.

Thank you for your interest and happy reading!


Warm Regards,

Dr. Jyoti Bajpai 
General Secretary 
Immuno-Oncology Society Of India
Terms & Conditions
+
Refund Policy
+